MSD's COVID-19 Pill Molnupiravir Gains First Approval In UK
To Be Marketed As Lagevrio
The UK becomes the first country to grant a marketing authorization for the oral treatment which could help cut hospitalizations and deaths by half.
You may also be interested in...
As well as hedging investors’ portfolios against the effects of pandemic waves, the stock prices of Pfizer and Merck & Co seem to be negatively correlated to each other, just as their pandemic-related revenues are to their traditional drug sales.
Strides has pushed back US revenue guidance of $225m-$250m by a year to FY23 amid price erosion and substantial competition in the market. Meanwhile, the firm’s CEO says Merck’s molnupiravir and Pfizer’s Paxlovid are not seen impacting COVID-19 vaccine uptake as boosters and immunization for travel will drive continued demand. The Indian company expects to book Sputnik Light sales from Q4.
Roche has bowed out of the race to develop an oral COVID-19 therapy, leaving a lucrative but likely short-lived market for its rivals.